(E)-N-[4-(3,4-Dihydro-1H-isoquinolin-2-YL)-butyl]-3-phenyl-acrylamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-N-[4-(3,4-Dihydro-1H-isoquinolin-2-YL)-butyl]-3-phenyl-acrylamide
• 英文别名: (E)-N-[4-(3,4-dihydro-1H-isoquinolin-2-yl)butyl]-3-phenylprop-2-enamide
• 化学式: C₂₂H₂₆N₂O
• 分子量: 334.5
• InChiKey: GQPJBOOQHWEOKT-OUKQBFOZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Method for in vivo detection of antipsychotic properties of dopamine D3 receptor ligands
  申请人：Institut National de la Santé et de la Recherche Médicale (INSERM)

  公开号：EP1462117A1

  公开（公告）日：2004-09-29

  The invention provides a method in vivo detecting anti-D3 receptor activity of dopamine D3 receptor ligands. The method of the invention makes use of a NMDA glutamate receptor antagonist to induce D3-mediated behavioral abnormalities and assess reversing effects of candidate ligands. The invention further relates to the use of a dopamine D3 receptor partial agonist or antagonist for the treatment of a substance-induced psychotic disorder or a dyskinesia associated with associated with dopamine agonist therapy.

  本发明提供了一种体内检测多巴胺 D3 受体配体抗 D3 受体活性的方法。本发明的方法利用 NMDA 谷氨酸受体拮抗剂诱导 D3 介导的行为异常，并评估候选配体的逆转效应。本发明进一步涉及使用多巴胺 D3 受体部分激动剂或拮抗剂治疗物质诱发的精神障碍或与多巴胺激动剂治疗相关的运动障碍。
• Essential tremor diagnostic and treatment
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP1591455A1

  公开（公告）日：2005-11-02

  The invention relates to an in vitro method for diagnosing essential tremor wherein a mutation of dopamine D3 receptor gene or protein is sought. The invention further relates to the use of a ligand having anti-dopamine D3 receptor activity for treatment of essential tremor.

  本发明涉及一种诊断本质性震颤的体外方法，其中寻找多巴胺 D3 受体基因或蛋白的突变。本发明还涉及一种具有抗多巴胺 D3 受体活性的配体用于治疗本质性震颤的用途。
• ESSENTIAL TREMOR DIAGNOSTIC AND TREATMENT
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP1740610A2

  公开（公告）日：2007-01-10
• [EN] IN VIVO METHOD FOR DETECTING DOPAMINE D3 RECEPTORS LIGANDS.<br/>[FR] METHODE DE DETECTION IN VIVO DE LIGANDS DES RECEPTEURS DOPAMINERGIQUES D3.
  申请人：INST NAT SANTE RECH MED

  公开号：WO2004084952A1

  公开（公告）日：2004-10-07

  The invention provides a method in vivo detecting anti-D3 receptor activity of dopamine D3 receptor ligands. The method of the invention makes use of a NMDA glutamate receptor antagonist to induce D3-mediated behavioral abnormalities and assess reversing effects of candidate ligands. The invention further relates to the use of a dopamine D3 receptor partial agonist or antagonist for the treatment of a substance-induced psychotic disorder or a dyskinesia associated with associated with dopamine agonist therapy.
• [EN] ESSENTIAL TREMOR DIAGNOSTIC AND TREATMENT<br/>[FR] DIAGNOSTIC ET TRAITEMENT DU TREMBLEMENT ESSENTIEL
  申请人：INST NAT SANTE RECH MED

  公开号：WO2005105839A2

  公开（公告）日：2005-11-10

  The invention relates to an in vitro method for diagnosing essential tremor wherein a mutation of dopamine D3 receptor gene or protein is sought. The invention further relates to the use of a ligand having anti-dopamine D3 receptor activity for treatment of essential tremor.